Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

Citation

  • Authors: Gregory, S. H., Mott, S., Phung, J., Lee, J., Moise, L., McMurry, J. A., Martin, W., De Groot, A. S.
  • Year: 2009
  • Journal: Vaccine 27 5299-306
  • Applications: in vivo / DNA / in vivo-jetPEI

Method

The HLA class II DNA construct was mixed with in vivo-jetPEI. To promote mucosal immunity, HLA-DRB1- transgenic mice were inoculated intratracheally (i.t.) three times at 2-week intervals (i.e., on days 0, 14 and 28) with 25 µg DNA/50 µl saline. On days 42 and 56, the mice were boosted i.t. with 25µg/50 µl aliquots of the same class-II-restricted peptides encoded by the construct.

Abstract

Francisella tularensis, the etiological agent of tularemia, is one of the most infectious bacterial pathogens known. No vaccine is currently approved for public use. Previously, we identified epitopes recognized specifically by T cells obtained from individuals following infection with F. tularensis. Here, we report that a subunit vaccine constructed based upon these epitopes elicited protective immunity in "humanized" HLA class II (DRB1*0401) transgenic mice. Vaccinated mice challenged intratracheally with a lethal dose of F. tularensis (Live Vaccine Strain) exhibited a rapid increase in pro-inflammatory cytokine production and diminished number of organisms in the lungs, and a concurrent increased rate of survival. These results demonstrate the efficacy of an epitope-based tularemia vaccine and suggest that such an approach might be widely applicable to the development of vaccines specific for intracellular bacterial pathogens.

Go to